Encapsulated Stem Cell–Derived β Cells Exert Glucose Control in Patients with Type 1 Diabetes

Researchers conducting a phase I/II, open-label, multicenter trial aimed at optimizing cell engraftment with device-encapsulated pancreatic precursor cells, and reported interim, one-year outcomes in one study group that received two–threefold higher cell doses in devices with an optimized membrane perforation pattern